C2I hosts exciting private summer social!

Thank you to those who attended C2I's private summer social on July 11th! It was a pleasure to introduce our new facilities and hear from past incubator alumni, current start-up companies, incoming start-ups, and potential board & advisory members.

C2I Alumni, Nano-C, Completes $11.5 Million Funding Round: Secures Investment from Analog Devices

Nano-C, a C2I alumni, is a leading developer in nanostructured carbon for energy and electronics applications. Congratulations upon completion of $11.5 million round of funding and a final $3 million tranche from Chairman Ray Strata of Analog Devices. Some of their products include: • Next Generation Memory - Nantero is using Nano-C's carbon nanotubes in its NRAM chips which have read-write speeds of DRAM with lower power consumption. Key investors include Cisco Investments, Dell Technologies Capital, Kingston Technology Corporation, CFT Capital, and Schlumberger. • Photovoltaic Devices - The Performance Materials Division of Merck KGaA, plans to use custom small molecules from Nano-C for OP

U.S. Department of Defense Awards $2M Grant to Frequency Therapeutics

Congratulations to our alumni, Frequency Therapeutics, on receiving a $2 million U.S. Department of Defense Hearing and Balance Research Award grant to investigate Progenitor Cell Activation (PCA Regeneration). Frequency aims to use PCA Regeneration technology to "restore hearing that has been lost as a result of military service-related injuries". Frequency has developed their unique platform that targets the root of disease through local deliveries of small molecules to induce the regeneration of neuronal connections and hair cells for hearing. Over 50% of battlefield situational awareness comes from hearing for active duty soldiers. Combat experience peak noise levels can reach 180 dB, an

Welcome to C2I, JA Bio Inc.!

The C2I team is excited to announce our new resident company, JA Bio Inc. JA Bio Inc. is a startup bio-technology company focused on anti-cancer cell immune therapeutics discovery and development. Their R&D consists of: → Tumor immunotherapy industry biomedical research. → Anti-cancer immune cells, protein, DNA, and growth factors of drug and technology research and development. → Related equipment, reagents process research, and development for licensing and clinic retail. Their Business activities include: → Medical technology development and technical services. →Technology support & technical consultation. → Medical equipment import & export agents allowed by legal licensing distribution.

C2I Alumni, LayerBio Inc., Awarded $1.2 Million from NIH to Develop Sustained-Release Glaucoma Drug

Congratulations to our alumni, LayerBio Inc., for being awarded $1.2 million SBIR grant to develop their sustained-release formula of the glaucoma drug travoprost. Glaucoma is the leading cause of irreversible blindness worldwide, and an estimated 2.2 million people in the U.S. suffer from glaucoma. Current treatment (topical eye drops) has limited effectiveness in preventing the progression of glaucoma. "Sustained-release formulations offer an important alternative to eye drops, because they provide around-the-clock coverage for patients suffering for glaucoma," said Dr. Ken Mandell, LayerBio's Founder and CEO. "They also overcome the issue of dosing noncompliance, a common problem among gl

Frequency Therapeutics’ Co-founder and VP, Will McLean, Ph.D., Named To MIT Technology Review’s 2018

Congratulations to our alumni, Frequency Therapeutics' Co-founder and VP, Will McLean, Ph.D. for being named MIT Technology Review's 2018 Innovators Under 35! Will McLean with the Frequency team have created a new field in regenerative medicine called PCA Regeneration. PCA Regeneration is a "platform with the potential to explore large populations of previously difficult-to-access progenitor cell types to drive drug development into new frontiers." He has made groundbreaking discoveries in regenerative technology seeking to reach in unmet needs including "demyelinating diseases such as alopecia, muscle indications including atrophy and wound care, gastrointestinal diseases, and diabetes." MI

Featured Posts
Recent Posts
Archive
Search By Tags

© 2019 by CreaGen Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

 

info@creagenbio.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | CreaGen C2I | Life Science | Lease Lab Space | Biotech